UK

Amid U.K. cutbacks, AstraZeneca plows $520M into manufacturing and R&D in France
Amid U.K. cutbacks, AstraZeneca plows $520M into manufacturing and R&D in France
Fierce Pharma
AstraZeneca
R&D
France
Brexit
UK
drug manufacturing
Flag link:
Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer
Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer
Pharmaforum
cancer
UK
NICE
Bayer
Vitrakvi
drug pricing
Flag link:
Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer
Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer
Fierce Pharma
Roche
Tecentriq
NICE
UK
Small-Cell Lung Cancer
Flag link:
The 4 biggest pharma market access stories of 2019
The 4 biggest pharma market access stories of 2019
Pharmaforum
biosimilars
UK
Orkambi
Vertex Pharmaceuticals
drug pricing
FDA
NICE
Flag link:
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Pharmaforum
Spark Therapeutics
Roche
UK
M&A
CMA
Flag link:
U.K. government vows to double dementia funding if reelected
U.K. government vows to double dementia funding if reelected
Fierce Biotech
UK
dementia
Flag link:
Secret US-UK talks on drug pricing revealed
Secret US-UK talks on drug pricing revealed
Pharmaforum
UK
Europe
trade
drug pricing
Flag link:
Ranking the Top 10 Biotech Clusters in Europe
Ranking the Top 10 Biotech Clusters in Europe
BioSpace
Europe
biotech
McKinsey
UK
Germany
France
Spain
The Netherlands
Flag link:
After years of battling, Vertex and the U.K. reach a deal for cystic fibrosis medicines
After years of battling, Vertex and the U.K. reach a deal for cystic fibrosis medicines
Stat
Vertex Pharmaceuticals
cystic fibrosis
UK
Flag link:
Eli Lilly to shutter neuroscience R&D center next year
Eli Lilly to shutter neuroscience R&D center next year
Fierce Biotech
Eli Lilly
UK
layoffs
R&D
Flag link:
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn
Fierce Pharma
Clovis Oncology
Rubraca
NICE
UK
PARP inhibitors
Flag link:
Bayer chooses UK for its AI-focused R&D hub
Bayer chooses UK for its AI-focused R&D hub
Pharmaforum
Bayer
R&D
artificial intelligence
UK
Flag link:
Aspen admits 1,800% U.K. price hike was wrong—and it'll pay $10M in penance
Aspen admits 1,800% U.K. price hike was wrong—and it'll pay $10M in penance
Fierce Pharma
CMA
drug pricing
Aspen
UK
Flag link:
Audit body warns of risks to medicine supplies in no-deal Brexit, despite preparations
Audit body warns of risks to medicine supplies in no-deal Brexit, despite preparations
Pharmaforum
Brexit
UK
Flag link:
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already
Fierce Pharma
M&A
UK
Spark Therapeutics
Roche
antitrust
CMA
Flag link:
Pharma companies admit to sharing 'sensitive' info to keep prices high
Pharma companies admit to sharing 'sensitive' info to keep prices high
Fierce Pharma
UK
generics
price fixing
collusion
King Pharmaceuticals
Alissa Healthcare
Flag link:
Factbox: Britain's insulin providers prepare for Brexit fallout
Factbox: Britain's insulin providers prepare for Brexit fallout
Yahoo/Reuters
Novo Nordisk
Eli Lilly
Sanofi
UK
Brexit
insulin
diabetes
Flag link:
Vertex deal for Scotland — no deal for England
Vertex deal for Scotland — no deal for England
Endpoints
Vertex Pharmaceuticals
cystic fibrosis
Scotland
England
UK
Symkevi
Orkambi
Flag link:
Drug companies pay for exclusive access to UK genetic data
Drug companies pay for exclusive access to UK genetic data
Biopharma Dive
UK
genetic database
Amgen
AstraZeneca
JNJ
GSK
Flag link:
UK cost watchdog recommends Novartis' blindness therapy Luxturna
UK cost watchdog recommends Novartis' blindness therapy Luxturna
Yahoo/Reuters
Novartis
gene therapy
Luxturna
UK
NICE
Spark Therapeutics
Flag link:

Pages